A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358

被引：0
|
作者：
Spear, M. A.
LoRusso, P.
Tolcher, A. W.
Lin, C.
Wang, D.
Heath, E.
Lloyd, G. K.
Cropp, G.
Papadopoulos, K. P.
机构：
[1] Nereus Pharmaceut, San Diego, CA USA
[2] Karmanos Canc Ctr, Detroit, MI USA
[3] Inst Drug Dev, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14097
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358
    Mita, Monica
    Spear, Matthew A.
    Yee, Lorrin K.
    Papadopoulos, K. P.
    Heath, Elisabeth
    Romero, Ofelia
    Lloyd, G. Kenneth
    Cropp, Gillian
    Mita, Alain
    LoRusso, Patricia
    CANCER RESEARCH, 2008, 68 (09)
  • [2] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Millward, Michael
    Mainwaring, Paul
    Mita, Alain
    Federico, Kristine
    Lloyd, G. K.
    Reddinger, Natasha
    Nawrocki, Steffan
    Mita, Monica
    Spear, Matthew A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1065 - 1073
  • [3] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Michael Millward
    Paul Mainwaring
    Alain Mita
    Kristine Federico
    G. K. Lloyd
    Natasha Reddinger
    Steffan Nawrocki
    Monica Mita
    Matthew A. Spear
    Investigational New Drugs, 2012, 30 : 1065 - 1073
  • [4] NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort
    Mita, M.
    Spear, M. A.
    Yee, L. K.
    Papadopoulos, K. P.
    Heath, E. I.
    Pilat, M.
    Romero, O.
    Lloyd, G. K.
    Mita, A.
    LoRuss, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 17 - 17
  • [5] Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel
    Millward, M.
    Mita, A.
    Spear, M. A.
    Federico, K. C.
    Lloyd, G. K.
    Cropp, G.
    Mita, M.
    Mainwaring, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Preclinical profile of NPI-2358, a tumor vascular disrupting agent.
    Lloyd, GK
    Wilson, L
    Bishop, J
    Nicholson, B
    Paladino, M
    Borgström, P
    Honess, DJ
    Tozer, GM
    Siemann, DW
    Mangold, G
    Kiso, Y
    Neuteboom, ST
    Hayashi, Y
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9033S - 9033S
  • [7] Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
    Mita, A. C.
    Yee, L. K.
    Papadopoulos, K. P.
    Heath, E. I.
    Romero, O.
    Lloyd, G. K.
    Cropp, G.
    Spear, M. A.
    Mita, M. M.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase 1 trial of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors or lymphomas
    Pilat, Mary Jo
    LoRusso, Patricia
    Spear, Matthew
    Yee, Lorrin
    Papadopoulos, K. P.
    Mita, Alain
    Heath, Elisabeth
    Federico, Kristine
    Reich, Steven
    Romero, Ofelia
    Lloyd, G. Kenneth
    Cropp, Gillian
    Mita, Monica
    CANCER RESEARCH, 2009, 69
  • [9] Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
    LoRusso, P.
    Yee, L.
    Papadopoulos, K. P.
    Tolcher, A. W.
    Romero, O.
    Wang, D.
    Heath, Elisabeth I.
    Lloyd, G. K.
    Longenecker, A.
    Neuteboom, S. C.
    Federico, K.
    Cropp, G.
    Spear, Matthew A.
    Mita, M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3437S - 3437S
  • [10] Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
    Mita, Monica M.
    Spear, Matthew A.
    Yee, Lorrin K.
    Mita, Alain C.
    Heath, Elisabeth I.
    Papadopoulos, Kyriakos P.
    Federico, Kristine C.
    Reich, Steven D.
    Romero, Ofelia
    Malburg, Lisa
    Pilat, MaryJo
    Lloyd, G. Kenneth
    Neuteboom, Saskia T. C.
    Cropp, Gillian
    Ashton, Edward
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5892 - 5899
12345